Tags: Health Topics | Chronic Pain | teva | study | chronic | headache

Teva to Discontinue Study for Chronic Headache Treatment

Teva to Discontinue Study for Chronic Headache Treatment
(Dreamstime)

Friday, 15 June 2018 11:53 AM

Israel's Teva Pharmaceutical Inc. said Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal.

Cluster headaches occur in cyclical patterns, or clusters, and are among the most painful types of headaches.

The drug, fremanezumab, is under review by the U.S. Food and Drug Administration for prevention of migraines in adults and the company hopes to launch the drug for the disorder as soon as mid-September.

Teva, which is counting on fremanezumab to help return to growth, also plans to continue testing the drug for the treatment of episodic cluster headaches.

"While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine," said Tushar Shah, senior vice president, head of global specialty clinical development at Teva.

Teva's U.S.-listed shares fell 1.6 percent to $23.4 in premarket trading.

© 2021 Thomson/Reuters. All rights reserved.


Health-News
Israel's Teva Pharmaceutical Inc. said Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal.
teva, study, chronic, headache
158
2018-53-15
Friday, 15 June 2018 11:53 AM
Newsmax Media, Inc.
 
Newsmax TV Live

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved